BioSphere Medical-TM- CHIEF EXECUTIVE OFFICER TO RESIGN
PAUL A. LOONEY APPOINTED CHAIRMAN

ROCKLAND,  Mass.  June 3, 2002 -- BioSphere  Medical Inc.  (Nasdaq:  BSMD) today
announced  that John  Carnuccio,  President and Chief  Executive  Officer,  will
resign  effective  September  1, 2002,  to pursue other  opportunities.  Paul A.
Looney,  who has served as a director since 1994, has been appointed Chairman of
the Board.  Robert Palladino,  Vice President and Chief Financial  Officer,  has
been promoted to Executive Vice President.  The Board of Directors has initiated
a search for a new Chief Executive Officer.

"BioSphere  Medical is entering a critical period of growth of its embolotherapy
product line. As a result, the company represents an attractive  opportunity for
a seasoned  executive,"  said Paul Looney.  "John  Carnuccio has made a valuable
contribution in building an exciting and growing medical device  franchise,  and
we wish him well in his future endeavors."

About BioSphere Medical, Inc.

BioSphere Medical, Inc., based in Rockland,  Massachusetts,  is a medical device
company  focused  on  embolotherapy,   the  treatment  of  tumors  and  vascular
malformations by occluding their blood supply. The Company is pioneering the use
of  patented  and  proprietary  bioengineered  microspheres  as a new  class  of
embolics.  BioSphere  Medical's lead products,  Embosphere(R)  Microspheres  and
EmboGold(TM)  Microspheres,  have  been  cleared  by the FDA for  marketing  for
hypervascularized  tumors and  vascular  malformations.  The Company has filed a
510(k)  application  and is  currently  awaiting a decision  by FDA on  expanded
labeling  that would  include  use of  Embosphere(R)  Microspheres  for  uterine
fibroid embolization (UFE) in the United States.  BioSphere Medical has received
CE Mark approval in the European Community and approvals in Canada and Australia
which  allow the Company to sell  Embosphere(R)  Microspheres  and  EmboGold(TM)
Microspheres  for use in  general  embolization  procedures,  including  uterine
fibroid  embolization.  For additional  information about BioSphere Medical, see
the Company's website at www.biospheremed.com.

Contact:
     BioSphere Medical, Inc.
     Kate Rajeck, 781-681-7928